Modifier 33 is appended to colonoscopy CPT codes when billing a commercial (non-Medicare) payer for a service that qualifies as a preventive screening under the Affordable Care Act. Its primary purpose is to signal that the procedure should be processed with no patient cost-sharing, as required by law. The modifier also covers a critical scenario: when a colonoscopy that began as a routine screening converts into a diagnostic or therapeutic procedure, such as a polyp removal, during the same session.
What Modifier 33 Communicates to the Payer
The ACA requires private insurers to fully cover colorectal cancer screening tests recommended by the U.S. Preventive Services Task Force (USPSTF), with no copays, coinsurance, or deductibles for the patient. Modifier 33 is the mechanism that tells a commercial payer, “This service is an ACA-designated preventive service.” Without it, the claim may process under the plan’s standard diagnostic benefits, potentially shifting costs to the patient that should have been waived.
The USPSTF gives colorectal cancer screening an “A” recommendation for adults aged 50 to 75 and a “B” recommendation for adults aged 45 to 49. Both grades trigger the ACA’s cost-sharing protections, so modifier 33 applies across the entire 45-to-75 age range when the colonoscopy is performed for screening purposes on a commercially insured patient.
The Screening-to-Diagnostic Conversion Scenario
This is where modifier 33 matters most in day-to-day colonoscopy coding. A patient comes in for a routine screening colonoscopy, but the physician finds and removes a polyp. The procedure has now converted from a pure screening into a therapeutic one, and the CPT code must change to reflect the work actually performed (for example, a polypectomy code rather than a basic screening colonoscopy code).
Without modifier 33, the payer would see a therapeutic procedure code and process the claim as diagnostic, applying the patient’s deductible and coinsurance. Appending modifier 33 tells the payer the procedure started as a preventive screening, preserving the patient’s cost-sharing protections. The U.S. Department of Health and Human Services has clarified that polyp removal is an integral part of a screening colonoscopy, so privately insured patients should not face out-of-pocket costs for it.
The intent at the time the procedure was scheduled is the key factor. If the colonoscopy was ordered as a screening for an average-risk or age-appropriate patient and then converted to diagnostic or therapeutic based on intraoperative findings, modifier 33 applies. If the colonoscopy was ordered from the start because of symptoms, a prior abnormal test, or surveillance of a known condition, it is diagnostic by intent and modifier 33 does not apply.
Modifier 33 vs. Modifier PT for Medicare
Modifier 33 is only for commercial payers. Medicare uses a separate modifier, PT, for the same concept. Modifier PT is appended to the diagnostic or therapeutic CPT code when a colonoscopy that began as a Medicare-covered screening converts to a diagnostic procedure during the session. The billing logic is similar, but the modifiers are not interchangeable.
There is also a financial difference. For Medicare patients, the deductible is waived on a converted screening colonoscopy billed with modifier PT, but the patient may still owe coinsurance. For commercially insured patients, the ACA’s protections are broader: modifier 33 should eliminate all patient cost-sharing, including coinsurance, for the preventive portion of the service.
Sedation and Anesthesia Services
Modifier 33 is not limited to the colonoscopy procedure code itself. CMS guidance confirms that coinsurance and deductible are waived for moderate sedation services when they are furnished in support of a screening colonoscopy and reported with modifier 33. If your practice bills sedation separately for a screening colonoscopy on a commercial plan, appending modifier 33 to the sedation code helps ensure the payer processes it under preventive benefits as well.
Diagnosis Code Pairing
When a screening colonoscopy converts to diagnostic, the claim should carry both the screening diagnosis code (Z12.11, encounter for screening for malignant neoplasm of colon) and the code for whatever was found during the procedure (for example, D12.6 for a benign neoplasm of the colon). Listing the screening diagnosis first reinforces the preventive intent of the visit and supports the use of modifier 33.
Documentation That Supports the Modifier
The medical record needs to clearly establish that the colonoscopy was scheduled and initiated as a preventive screening. Key elements include the ordering provider’s reason for the referral, the patient’s screening eligibility (age, risk status, and interval since last screening), and a procedural note confirming that any diagnostic or therapeutic action was prompted by findings during the screening itself, not by pre-existing symptoms. If the documentation reads as though the colonoscopy was ordered to evaluate a complaint or monitor a known condition, modifier 33 will not hold up in an audit.
Common Situations Where Modifier 33 Does Not Apply
- Medicare patients: Use modifier PT instead for screening-to-diagnostic conversions.
- Surveillance colonoscopies: A colonoscopy performed because of a personal history of polyps or colorectal cancer is surveillance, not screening. These are diagnostic by intent regardless of the patient’s age.
- Symptom-driven procedures: If the patient was referred because of rectal bleeding, a change in bowel habits, unexplained anemia, or another symptom, the colonoscopy is diagnostic from the start.
- Grandfathered health plans: The ACA’s preventive services mandate does not apply to health plans that were in place before September 23, 2010, and have not been substantially changed. Modifier 33 may not trigger cost-sharing waivers on these plans.
Before submitting a claim, it is worth confirming the specific payer’s requirements. While modifier 33 follows a standard ACA framework, individual commercial insurers occasionally have their own processing rules or require additional documentation for converted screening procedures.